| Transplant (n = 20) | Non-transplant (n = 23) | P |
---|---|---|---|
Age (years), median, range | 42 (27–60) | 58 (21–79) | 0.003 |
Gender, no. (%) | 0.106 | ||
 Male | 10 (50.0%) | 17 (73.9%) |  |
 Female | 10 (50.0%) | 6 (26.1%) |  |
Median WBC (range), × 109/L | 2.73 (1.10–12.00) | 2.91 (1.34–7.36) | 0.759 |
Median NE (range), × 109/L | 0.85 (0.04–2.27) | 0.92 (0.16–4.92) | 0.439 |
Median HGB (range), g/L | 65 (30–138) | 69 (36–84) | 0.706 |
Median PLT (range), × 109/L | 41.5 (3–234) | 82 (8–282) | 0.179 |
MDS subtypes (WHO, 2016), no. (%) | 0.290 | ||
 MDS-SLD | 2 (10.0%) | 0 (0.0%) |  |
 MDS-MLD | 3 (15.0%) | 1 (4.3%) |  |
 MDS-RS-SLD | 0 (0.0%) | 2 (8.7%) |  |
 MDS-RS-MLD | 1 (5.0%) | 2 (8.7%) |  |
 MDS with isolated 5q-deletion | 0 (0.0%) | 0 (0.0%) |  |
 MDS-EB-1 | 5 (25.0%) | 5 (21.8%) |  |
 MDS-EB-2 | 8 (40.0%) | 13 (56.5%) |  |
 MDS-U | 1 (5.0%) | 0 (0.0%) |  |
Cytogenetic | 0.692 | ||
 Normal karyotype | 5 (25.0%) | 7 (30.4%) |  |
 Aberrant karyotype | 15 (75.0%) | 16 (69.6%) |  |
IPSS-R risk group, no. (%) | 0.128 | ||
 Very low | 0 (0.0%) | 0 (0.0%) |  |
 Low | 2 (10.0%) | 3 (13.0%) |  |
 Intermediate | 7 (35.0%) | 2 (8.7%) |  |
 High | 6 (30.0%) | 6 (26.1%) |  |
 Very high | 5 (25.0%) | 12 (52.2%) |  |
Treatment, no. (%) | |||
 Cytoreductive treatments pre-transplantation | 11 (55.0%) | 0 (0.0%) |  |
 Cytoreductive treatments without HSCT | 0 (0.0%) | 12 (52.2%) |  |
 Immunoregulatory | 0 (0.0%) | 5 (21.7%) |  |
 Supportive care | 0 (0.0%) | 6 (26.1%) |  |
Leukemia transformation, no. (%) | 6 (30.0%) | 2 (8.3%) | 0.115 |
Median time from diagnosis to leukemia transformation, months (range) | 7 (1–20) | 12 (9–15) | 0.249 |